Abstract 10P
Background
Engraftment of cancer cells to liver pre-metastatic niches requires complex interaction with liver sinusoidal endothelial cells (LSECs). Intracellular gap (iGap) formation in LSECs is caused by the destruction of fenestrae and appears under pathological conditions. Here, we aimed to explore the novel role of LSECs-iGap in liver metastasis of cancer cells.
Methods
Mouse models using acetaminophen (APAP) or thioacetamide (TAA) followed by intrasplenic injection of hepatocellular carcinoma (HCC) cell line, Hepa1-6 cells, to assess the LSECs-iGap formation. Functional effects of LSECs-iGap on cancer cells were analyzed using MMPs inducer, monocrotaline and inhibitor, doxycycline and MMP2/9 inhibitor. Morphological and molecular features of LSECs-iGap were examined using in vivo mouse models and in vitro co-culture system with electron microscopy, 3 dimensions tomographic reconstruction image (3D-TRI), RNA-sequencing, cytokine array and endothelial trans-endothelial migration assay. Biopsy specimens from 98 patients with HCC were statistically evaluated.
Results
APAP-induced liver injury and TAA-induced fibrotic liver resulted in LSECs-iGap formation, which positively correlated with increased numbers of metastatic foci after Hepa1-6 cells injection. In addition, Hepa1-6 cells induced IL-23-dependent TNF-α secretion by LSECs and triggered LSECs-iGap formation, toward which their processes protruded to transmigrate into the liver parenchyma. TNF-α caused depolymerization of F-actin and increased MMP9, ICAM1, and CXCLs expression in LSECs. Moreover, high expression of ICAM1 and MMP9 was significantly associated with intrahepatic metastasis and overall survival of patients with HCC. Blocking MMP9 activity by doxycycline or MMP-2/9 inhibitor eliminated LSECs-iGap formation and attenuated liver metastasis of Hepa1-6 cells.
Conclusions
This study revealed that cancer cells induced LSEC-iGap formation via pro-inflammatory paracrine mechanisms and proposed MMP9 as a novel target for blocking cancer cell metastasis to the liver.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H.H. Truong.
Funding
Japan Agency for Medical Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09